Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis

Abdollah, Firas; Gandaglia, Giorgio; Thuret, Rodolphe; Schmitges, Jan; Tian, Zhe; Jeldres, Claudio; Passoni, Niccolò; Briganti, Alberto; Shariat, Shahrokh F.; Perrotte, Paul; Montorsi, Francesco; Karakiewicz, Pierre I.; Sun, Maxine

doi:10.1016/j.canep.2013.02.002

Cited by 235 publications

(170 citation statements)

References 34 publications

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…Approximately 75% of patients with bladder cancer present with non-muscle-invasive bladder cancer (NMIBC) that is either confined to the mucosa (stage Ta, CIS) or to the submucosa (stage T1), while further 25% of patients present with muscle-invasive bladder cancer (MIBC) 2 . Non-muscle-invasive bladder tumours can be effectively treated in a bladder-conservative approach by transurethral resection and adjuvant intravesical therapy.…”

Section: Introductionmentioning

confidence: 99%

PAK5 mediates cell: cell adhesion integrity via interaction with E-cadherin in bladder cancer cells

Ismail

Halaçlı

Babteen

et al. 2017

Biochemical Journal

View full text Add to dashboard Cite

Urothelial bladder cancer is a major cause of morbidity and mortality worldwide, causing an estimated 150,000 deaths per year. Whilst non-muscle-invasive bladder tumours can be effectively treated, with high survival rates, many tumours recur, and some will progress to muscle-invasive disease with a much poorer long term prognosis. Thus there is a pressing need to understand the molecular transitions occurring within the progression of bladder cancer to an invasive disease. Tumour invasion is often associated with a down regulation of E-cadherin expression concomitant with a suppression of cell: cell junctions and decreased levels of E-cadherin expression have been reported in higher grade urothelial bladder tumours. We find that expression of E-cadherin in a panel of bladder cancer cell lines correlated with the presence of cell: cell junctions and the level of PAK5 expression. Interestingly exogenous PAK5 has recently been described to be associated with cell: cell junctions and we now find that endogenous PAK5 is localised to cell junctions and interacts with an E-cadherin complex. Moreover, depletion of PAK5 expression significantly reduced junctional integrity. These data suggest a role for PAK5 in maintaining junctional stability and we find that in both our own patient samples and a commercially available datasets that PAK5mRNA levels are reduced in human bladder cancer compared to normal controls. Taken together this study proposes that PAK5 expression levels could be used as a novel prognostic marker for bladder cancer progression. PAK5 mediates cell: cell adhesion integrity via interaction with E-cadherin in bladder cancer cells AbstractUrothelial bladder cancer is a major cause of morbidity and mortality worldwide, causing an estimated 150,000 deaths per year. Whilst non-muscle-invasive bladder tumours can be effectively treated, with high survival rates, many tumours recur, and some will progress to muscle-invasive disease with a much poorer long term prognosis. Thus there is a pressing need to understand the molecular transitions occurring within the progression of bladder cancer to an invasive disease. Tumour invasion is often associated with a down regulation of E-cadherin expression concomitant with a suppression of cell: cell junctions and decreased levels of Ecadherin expression have been reported in higher grade urothelial bladder tumours.We find that expression of E-cadherin in a panel of bladder cancer cell lines correlated with the presence of cell: cell junctions and the level of PAK5 expression.Interestingly exogenous PAK5 has recently been described to be associated with cell: cell junctions and we now find that endogenous PAK5 is localised to cell junctions and interacts with an E-cadherin complex. Moreover, depletion of PAK5 expression significantly reduced junctional integrity. These data suggest a role for PAK5 in maintaining junctional stability and we find that in both our own patient samples and a commercially available datasets that PAK5mRNA levels are reduced in human bladder c...

show abstract

Section: Introductionmentioning

confidence: 99%

PAK5 mediates cell: cell adhesion integrity via interaction with E-cadherin in bladder cancer cells

Ismail

Halaçlı

Babteen

et al. 2017

Biochemical Journal

View full text Add to dashboard Cite

show abstract

“…As a result of improved bladder cancer management in the USA, a significant increase in 5-year survival rates has been observed for all urothelial tumor stages except for patients with metastatic disease [26]. In metastatic bladder cancer, effective tumor suppression necessitates an intact immune system [27,4].…”

Section: Inflammation and Bladder Cancermentioning

confidence: 99%

Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?

et al. 2015

View full text Add to dashboard Cite

Programmed death-ligand 1 (PD-L1) is a cell surface protein which is mainly expressed on immune cells as well as on cancer cells and functions as a co-stimulatory molecule for T lymphocytes. It is capable of inducing apoptosis in T-cells via PD-1 which leads to impaired cytokine production and loss of cytotoxicity of activated T-cells. This represents a possible escape mechanism for cancer cells. Tumor infiltration by mononuclear cells and tumor aggressiveness was found to be associated with PD-L1 expression. In light of possible autoimmunological side effects, it remains currently unclear which patient will benefit most from this novel therapeutic approach. Furthermore, immunohistochemistry for PD-L1 has not been well standardized until now. In addition, the combination of chemotherapy with checkpoint inhibitors in different clinical settings needs to be established for the near future in order to avoid overtreatment and also unnecessary cost expenditures for the health care system.

show abstract

“…1 Since the introduction of cisplatin-based combination chemotherapy more than 20 years ago, there has been little improvement in mortality for patients with metastatic bladder cancer. 2 There is growing interest in definitive local therapy for patients with metastatic cancer.…”

Section: Introductionmentioning

confidence: 99%

Radical cystectomy in patients with disseminated disease: An assessment of perioperative outcomes using the National Surgical Quality Improvement Program database

Wallis

Khana

Hajiha

et al. 2017

CUAJ

View full text Add to dashboard Cite

Introduction: We sought to determine the effect of the presence of disseminated disease on perioperative outcomes following radical cystectomy for bladder cancer. Methods: We identified 4108 eligible patients who underwent radical cystectomy for bladder cancer using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database. We matched patients with disseminated cancer at the time of surgery to those without disseminated cancer using propensity scores. The primary outcome of interest was major complications (death, reoperation, cardiac or neurological event). Secondary outcomes included pulmonary, infectious thromboembolic, and bleeding complications, in addition to prolonged length of stay. Generalized estimating equations were used to examine the association between disseminated cancer and the development of complications. Results: Following propensity score matching and adjusting for the type of urinary diversion, radical cystectomy in patients with disseminated disease was associated with a significant increase in major complications (8.6% vs. 4.0%; odds ratio [OR] 2.50; 95% confidence interval [CI] 1.02-6.11; p=0.045). The presence of disseminated disease was associated with an increase in pulmonary complications (5.8% vs. 1.2%; OR 5.17. 95% CI 1.00-26.66. p=0.049), but not infectious complications, venous thromboembolism, bleeding requiring transfusion, and prolonged length of stay (p values 0.07-0.79). Conclusions: Patients with disseminated cancer undergoing cystectomy are more likely to experience major and pulmonary complications. The strength of these conclusions is limited by sample size, selection bias inherent in observational data, and a lack of specific oncological detail in the database.

show abstract

Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis

Cited by 235 publications

References 34 publications

PAK5 mediates cell: cell adhesion integrity via interaction with E-cadherin in bladder cancer cells

PAK5 mediates cell: cell adhesion integrity via interaction with E-cadherin in bladder cancer cells

Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?

Radical cystectomy in patients with disseminated disease: An assessment of perioperative outcomes using the National Surgical Quality Improvement Program database

Contact Info

Product

Resources

About